Brokers Offer Predictions for IceCure Medical Q3 Earnings

IceCure Medical Ltd. (NASDAQ:ICCM) – Stock analysts at Brookline Capital Markets cut their Q3 2026 earnings per share estimates for IceCure Medical in a report released on Wednesday, August 12th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will earn ($0.83) per share for the quarter, down from their previous estimate of ($0.56). The consensus estimate for IceCure Medical’s current full-year earnings is ($4.61) per share. Brookline Capital Markets also issued estimates for IceCure Medical’s Q4 2026 earnings at ($0.84) EPS, FY2026 earnings at ($4.61) EPS, FY2027 earnings at ($3.61) EPS, FY2028 earnings at ($2.26) EPS and FY2029 earnings at $0.41 EPS.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($1.64) earnings per share (EPS) for the quarter. IceCure Medical had a negative return on equity of 174.26% and a negative net margin of 427.67%.The company had revenue of $0.91 million during the quarter.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a report on Friday, July 17th. Alliance Global Partners began coverage on shares of IceCure Medical in a research report on Monday, May 4th. They issued a “buy” rating on the stock. Wall Street Zen raised shares of IceCure Medical to a “sell” rating in a research note on Sunday, July 12th. Finally, Maxim Group decreased their target price on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, IceCure Medical currently has an average rating of “Moderate Buy” and a consensus price target of $52.50.

IceCure Medical Price Performance

Shares of NASDAQ ICCM opened at $2.82 on Monday. IceCure Medical has a 1-year low of $2.12 and a 1-year high of $42.00. The business’s fifty day moving average price is $3.91 and its two-hundred day moving average price is $9.60. The firm has a market capitalization of $9.67 million, a PE ratio of -0.33 and a beta of 0.47.

Institutional Investors Weigh In On IceCure Medical

Several institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in shares of IceCure Medical during the 4th quarter worth about $39,000. Concurrent Investment Advisors LLC acquired a new position in shares of IceCure Medical during the fourth quarter valued at approximately $48,000. Finally, Jane Street Group LLC acquired a new position in shares of IceCure Medical during the fourth quarter valued at approximately $67,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.